ARCT
Arcturus Therapeutics Holdings Inc.
+1.99 (+12.76%)17.59USD565K成交股數500M市值–本益比(近四季)17.0股價營收比-89.5%營收年增(近四季)2026-11-09下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 0.00 |
| 近 180 天 淨額 | 0.00 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-15 | 08-20 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 1.2K | 16.56 | 21K | 222K | SEC |
| 2025-08-15 | 08-19 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 1.2K | 16.56 | 21K | 222K | SEC |
| 2024-10-15 | 10-16 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 12.0K | 20.76 | 249K | 435K | SEC |
| 2024-06-14 | 06-18 | FARRELL PETER C | Director | M 選擇權執行 | 3.1K | – | – | 55.7K | SEC |
| 2024-06-14 | 06-18 | BARLOW JAMES F | Director | M 選擇權執行 | 3.1K | – | – | 13.1K | SEC |
| 2024-06-14 | 06-18 | Marquet Magda | Director | M 選擇權執行 | 3.1K | – | – | 3.1K | SEC |
| 2024-06-14 | 06-18 | Markels John | Director | M 選擇權執行 | 3.1K | – | – | 3.1K | SEC |
| 2024-06-14 | 06-18 | HOLMES EDWARD W | Director | M 選擇權執行 | 3.1K | – | – | 3.1K | SEC |
| 2024-06-14 | 06-18 | Marantz Jing L. | Director | M 選擇權執行 | 3.1K | – | – | 3.1K | SEC |
| 2024-06-12 | 06-14 | SASSINE ANDY | Chief Financial Officer | S 公開市場賣出 | 50.0K | 32.03 | 1.6M | 221K | SEC |
| 2024-06-05 | 06-07 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 114 | 45.00 | 5K | 447K | SEC |
| 2024-06-03 | 06-04 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 26.0K | 40.01 | 1.0M | 447K | SEC |
| 2024-03-25 | 03-27 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 17.4K | 35.02 | 611K | 473K | SEC |
| 2024-03-19 | 03-21 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 8.6K | 35.01 | 300K | 491K | SEC |
| 2023-11-01 | 11-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 18.72 | 94K | 499K | SEC |
| 2023-10-02 | 10-04 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 25.61 | 128K | 504K | SEC |
| 2023-09-01 | 09-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 31.45 | 157K | 509K | SEC |
| 2023-08-15 | 08-17 | SASSINE ANDY | Chief Financial Officer | A 獲配股票 | 1.2K | 17.37 | 21K | 271K | SEC |
| 2023-08-01 | 08-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 34.91 | 175K | 514K | SEC |
| 2023-07-14 | 07-18 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 4.5K | 9.04 | 41K | 5.5K | SEC |
| 2023-07-14 | 07-18 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 1.4K | 4.99 | 7K | 6.9K | SEC |
| 2023-07-14 | 07-18 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 1.0K | 14.12 | 15K | 7.9K | SEC |
| 2023-07-14 | 07-18 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 25.0K | 35.01 | 875K | 519K | SEC |
| 2023-07-14 | 07-18 | Kummerfeld Keith C | See Remarks | S 公開市場賣出 | 7.0K | 35.00 | 244K | 950 | SEC |
| 2023-07-03 | 07-07 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 28.75 | 144K | 544K | SEC |
| 2023-06-01 | 06-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 27.16 | 136K | 549K | SEC |
| 2023-05-11 | 05-12 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 7.9K | 30.24 | 240K | 554K | SEC |
| 2023-05-10 | 05-12 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 17.1K | 30.00 | 512K | 562K | SEC |
| 2023-05-01 | 05-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 25.93 | 130K | 579K | SEC |
| 2023-04-18 | 04-19 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 1.0K | 14.12 | 15K | 2.0K | SEC |
| 2023-04-18 | 04-19 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 4.5K | 9.04 | 41K | 6.5K | SEC |
| 2023-04-18 | 04-19 | Kummerfeld Keith C | See Remarks | M 選擇權執行 | 1.4K | 4.99 | 7K | 7.9K | SEC |
| 2023-04-18 | 04-19 | Kummerfeld Keith C | See Remarks | S 公開市場賣出 | 7.0K | 28.18 | 196K | 950 | SEC |
| 2023-04-03 | 04-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出(10b5-1) | 5.0K | 25.38 | 127K | 584K | SEC |
| 2023-03-06 | 03-08 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 5.0K | 16.07 | 80K | 589K | SEC |
| 2022-12-15 | 12-19 | Marquet Magda | Director | P 公開市場買進 | 2.2K | 18.00 | 40K | 24.9K | SEC |
| 2022-11-23 | 11-28 | Payne Joseph E | President and CEO | P 公開市場買進 | 5.0K | 16.51 | 83K | 1.5M | SEC |
| 2022-08-15 | 08-17 | SASSINE ANDY | Chief Financial Officer | A 獲配股票 | 1.1K | 18.42 | 20K | 269K | SEC |
| 2022-01-04 | 01-06 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 8.1K | 40.00 | 324K | 594K | SEC |
| 2021-12-16 | 12-20 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 3.6K | 40.00 | 145K | 603K | SEC |
| 2021-12-08 | 12-10 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 6.4K | 40.00 | 255K | 606K | SEC |
| 2021-11-01 | 11-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 44.41 | 444K | 613K | SEC |
| 2021-10-01 | 10-04 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 44.36 | 444K | 623K | SEC |
| 2021-09-01 | 09-02 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 55.86 | 559K | 633K | SEC |
| 2021-08-11 | 08-12 | Ultragenyx Pharmaceutical Inc. | Director | S 公開市場賣出 | 75.0K | 45.83 | 3.4M | 1.4M | SEC |
| 2021-08-10 | 08-12 | Ultragenyx Pharmaceutical Inc. | Director | S 公開市場賣出 | 725K | 55.44 | 40.2M | 1.5M | SEC |
| 2021-08-03 | 08-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 40.07 | 401K | 643K | SEC |
| 2021-04-01 | 04-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 42.95 | 430K | 653K | SEC |
| 2021-03-01 | 03-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 54.23 | 542K | 663K | SEC |
| 2021-02-01 | 02-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 75.31 | 753K | 673K | SEC |
| 2021-01-04 | 01-05 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 46.40 | 464K | 683K | SEC |
| 2020-12-09 | 12-10 | Ultragenyx Pharmaceutical Inc. | Director,TenPercentOwner | S 公開市場賣出 | 358K | 94.97 | 34.0M | 2.2M | SEC |
| 2020-12-08 | 12-10 | Ultragenyx Pharmaceutical Inc. | Director,TenPercentOwner | S 公開市場賣出 | 442K | 105.54 | 46.7M | 2.6M | SEC |
| 2020-12-01 | 12-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 96.19 | 962K | 693K | SEC |
| 2020-11-02 | 11-03 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 55.28 | 553K | 703K | SEC |
| 2020-10-01 | 10-02 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 42.83 | 428K | 713K | SEC |
| 2020-09-03 | 09-04 | Chivukula Pad | Chief Scientific Officer & COO | S 公開市場賣出 | 10.0K | 45.16 | 452K | 723K | SEC |
| 2020-06-12 | 06-12 | Kummerfeld Keith C | See Remarks | P 公開市場買進 | 450 | 33.33 | 15K | 950 | SEC |
| 2020-06-10 | 06-10 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 5.0K | 29.74 | 149K | 273K | SEC |
| 2020-06-10 | 06-10 | Payne Joseph E | President and CEO | P 公開市場買進 | 1.0K | 31.69 | 32K | 1.5M | SEC |
| 2020-05-20 | 05-22 | Ultragenyx Pharmaceutical Inc. | Director,TenPercentOwner | M 選擇權執行 | 600K | 16.00 | 9.6M | 3.0M | SEC |
| 2019-12-05 | 12-09 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 5.6K | 9.73 | 55K | 268K | SEC |
| 2019-12-03 | 12-05 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 10.0K | 10.00 | 100K | 258K | SEC |
| 2019-09-13 | 09-17 | Marquet Magda | Director | P 公開市場買進 | 2.3K | 10.58 | 24K | 22.7K | SEC |
| 2019-09-12 | 09-12 | Kummerfeld Keith C | See Remarks | P 公開市場買進 | 500 | 10.69 | 5K | 500 | SEC |
| 2019-08-29 | 08-30 | Payne Joseph E | President and CEO | P 公開市場買進 | 5.0K | 11.22 | 56K | 1.5M | SEC |
| 2019-08-23 | 08-26 | SASSINE ANDY | Chief Financial Officer | P 公開市場買進 | 10.0K | 10.90 | 109K | 248K | SEC |
| 2019-08-20 | 08-21 | FARRELL PETER C | Director | P 公開市場買進 | 4.4K | 10.85 | 48K | 43.0K | SEC |
| 2019-08-19 | 08-21 | FARRELL PETER C | Director | P 公開市場買進 | 4.7K | 11.02 | 52K | 38.5K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | 3.3M | 22.2M | 新進 | 新進 |
| 方舟(伍德) ARK Investment Management LLC | 2.9M | 19.5M | 新進 | 新進 |
| BlackRock, Inc. | 2.6M | 17.6M | 新進 | 新進 |
| Sumitomo Mitsui Trust Group, Inc. | 2.0M | 13.2M | 新進 | 新進 |
| Amova Asset Management Americas, Inc. | 2.0M | 13.1M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | 7.5M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 1.1M | 7.3M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 952K | 6.4M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 694K | 4.7M | 新進 | 新進 |
| AQR CAPITAL MANAGEMENT LLC | 675K | 4.5M | 新進 | 新進 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 648K | 4.4M | 新進 | 新進 |
| STATE STREET CORP | 570K | 3.8M | 新進 | 新進 |
| UBS Group AG | 491K | 3.3M | 新進 | 新進 |
| 德劭 D. E. Shaw & Co., Inc. | 392K | 2.6M | 新進 | 新進 |
| Empire Life Investments Inc. | 366K | 2.5M | 新進 | 新進 |
| Hennion & Walsh Asset Management, Inc. | 346K | 2.3M | 新進 | 新進 |
| 千禧 MILLENNIUM MANAGEMENT LLC | 337K | 2.3M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 310K | 2.1M | 新進 | 新進 |
| BNP PARIBAS FINANCIAL MARKETS | 262K | 1.8M | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 232K | 1.6M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 232K | 1.6M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 221K | 1.5M | 新進 | 新進 |
| HEARTLAND ADVISORS INC | 219K | 1.5M | 新進 | 新進 |
| NORTHERN TRUST CORP | 205K | 1.4M | 新進 | 新進 |
| JPMORGAN CHASE & CO | 196K | 1.3M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 135 +11 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 135 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 25.0M · 87.9% |
| 合計季末市值 | 166M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 6.1M |
|---|---|
| 與上期比 | -6.6% |
| 佔流通股數 | 21.45% |
| 日均成交量 | 2.0M |
| 回補天數 | 3.1 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 6.1M | -6.6% | 21.45% | 2.0M | 3.1 |
| 2026-08-14 | 6.5M | -9.4% | 22.96% | 662K | 9.9 |
| 2026-07-31 | 7.2M | +2.9% | 25.36% | 436K | 16.5 |
| 2026-07-15 | 7.0M | +3.0% | 24.64% | 654K | 10.7 |
| 2026-06-30 | 6.8M | +1.4% | 23.93% | 440K | 15.5 |
| 2026-06-15 | 6.7M | -0.3% | 23.60% | 379K | 17.7 |
| 2026-05-29 | 6.7M | +2.3% | 23.67% | 411K | 16.4 |
| 2026-05-15 | 6.6M | +2.1% | 23.13% | 496K | 13.3 |
| 2026-04-30 | 6.4M | +3.0% | 22.66% | 319K | 20.2 |
| 2026-04-15 | 6.3M | -3.1% | 22.00% | 436K | 14.3 |
| 2026-03-31 | 6.5M | +8.6% | 22.69% | 584K | 11.1 |
| 2026-03-13 | 5.9M | -2.4% | 20.89% | 550K | 10.8 |
| 2026-02-27 | 6.1M | -7.5% | 21.40% | 347K | 17.5 |
| 2026-02-13 | 6.6M | -4.5% | 23.13% | 441K | 14.9 |
| 2026-01-30 | 6.9M | -4.3% | 24.21% | 423K | 16.3 |
| 2026-01-15 | 7.2M | +0.4% | 25.29% | 571K | 12.6 |
| 2025-12-31 | 7.2M | -7.1% | 25.19% | 622K | 11.5 |
| 2025-12-15 | 7.7M | -1.3% | 27.11% | 783K | 9.8 |
| 2025-11-28 | 7.8M | -15.2% | 27.48% | 947K | 8.3 |
| 2025-11-14 | 9.2M | +32.5% | 32.40% | 1.0M | 9.1 |
| 2025-10-31 | 6.9M | +30.9% | 24.45% | 3.0M | 2.3 |
| 2025-10-15 | 5.3M | +3.2% | 18.68% | 1.0M | 5.1 |
| 2025-09-30 | 5.1M | -13.5% | 18.10% | 812K | 6.3 |
| 2025-09-15 | 5.9M | +9.9% | 20.92% | 467K | 12.7 |
| 2025-08-29 | 5.4M | +5.2% | 19.03% | 564K | 9.6 |
| 2025-08-15 | 5.1M | +17.7% | 18.10% | 865K | 6.0 |